Alnylam Pharma (ALNY) Tops Q1 EPS by 92c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.01), $0.92 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $594.19 million versus the consensus estimate of $588.75 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FOMC minutes from July 28-29th meeting
- Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates
- Target raises full-year sales forecast amid ongoing turnaround drive
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
